SPTX — Seaport Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 2042347 ·
Last close
$17.50
Market Cap
$927.99M
52W High
$23.00
52W Low
$14.85
ADV30
686,431
Next earnings
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts.
No quarterly fundamentals indexed for this ticker.

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -87,294,000 -74,881,000 249,009,000 341,554,000 -77,942,000
Dec 2024 0 -52,416,000 -46,879,000 315,777,000 340,626,000 -29,629,000

Peers — same industry

TickerNameMarket CapLastDaily %
PCRX Pacira BioSciences, Inc. $918.77M $23.35
PHAT Phathom Pharmaceuticals, Inc. $903.63M $11.33
OPK OPKO HEALTH, INC. $958.97M $1.27
LXRX LEXICON PHARMACEUTICALS, INC. $959.46M $2.16
ETON Eton Pharmaceuticals, Inc. $892.72M $32.59

News headlines (Yahoo Finance, 1h cache)

Assessing Seaport Therapeutics (SPTX) Valuation After Its Recent 10.2% One Day Share Price Move
2026-05-04 07:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.